3qn7 - Revision history

OCA at 17:14, 1 November 2023

OCA — Wed, 01 Nov 2023 17:14:15 GMT

←Older revision		Revision as of 17:14, 1 November 2023
Line 3:		Line 3:
	<StructureSection load='3qn7' size='340' side='right'caption='[[3qn7]], [[Resolution\|resolution]] 1.90Å' scene=''>		<StructureSection load='3qn7' size='340' side='right'caption='[[3qn7]], [[Resolution\|resolution]] 1.90Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[3qn7]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QN7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3QN7 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[3qn7]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QN7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3QN7 FirstGlance]. <br>
-	</td></tr><tr id='~~ligand~~'><td class="sblockLbl"><b>[[~~Ligand~~\|~~Ligands~~:]]</b></td><td class="sblockDat" id="~~ligandDat~~">~~<scene name='pdbligand=ZBR:1~~,~~3,5-TRIS(BROMOMETHYL)BENZENE'>ZBR</scene></td></tr>~~	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.9Å</td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>~~[[~~Related_structure~~\|~~Related:~~]]~~</b></td><td class="sblockDat"><div style='overflow: auto~~; ~~max-height: 3em;'>[[1lmw\|1lmw]], [[2nwn\|2nwn]]</div>~~</td></tr>	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ZBR:1,3,5-TRIS(BROMOMETHYL)BENZENE'>ZBR</scene></td></tr>
-	<tr id='~~gene~~'><td class="sblockLbl"><b>[[~~Gene~~\|~~Gene~~:]]</b></td><td class="sblockDat"~~>PLAU ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&~~id~~=9606 HUMAN])</td></tr>~~	+
-	~~<tr id='activity'><td class~~="~~sblockLbl~~"><~~b>Activity:</b></td><td class~~=~~"sblockDat"><span class~~=~~'plainlinks'>[https~~:~~//en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator]~~, ~~with EC number [https://www.brenda~~-~~enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73]~~ </~~span~~></td></tr>	+
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3qn7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qn7 OCA], [https://pdbe.org/3qn7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3qn7 RCSB], [https://www.ebi.ac.uk/pdbsum/3qn7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3qn7 ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3qn7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qn7 OCA], [https://pdbe.org/3qn7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3qn7 RCSB], [https://www.ebi.ac.uk/pdbsum/3qn7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3qn7 ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[[https://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[https://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>	+	[https://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[https://omim.org/entry/601709 601709]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>
	== Function ==		== Function ==
-	[[https://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.	+	[https://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 30:		Line 28:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	~~[[Category: U-plasminogen activator]]~~	+	[[Category: Angelini A]]
-	[[Category: Angelini, A]]	+	[[Category: Cendron L]]
-	[[Category: Cendron, L]]	+	[[Category: Heinis C]]
-	[[Category: Heinis, C]]	+	[[Category: Touati J]]
-	[[Category: Touati, J]]	+	[[Category: Winter G]]
-	[[Category: Winter, G]]	+	[[Category: Zanotti G]]
-	[[Category: Zanotti, G]]	+
-	~~[[Category: Bicyclic peptide inhibitor]]~~	+
-	~~[[Category: Chymotrypsin fold]]~~	+
-	~~[[Category: Extracellular]]~~	+
-	~~[[Category: Hydrolase-hydrolase inhibitor complex]]~~	+
-	~~[[Category: Serine protease~~]]	+

OCA at 06:15, 8 June 2022

OCA — Wed, 08 Jun 2022 06:15:44 GMT

←Older revision		Revision as of 06:15, 8 June 2022
Line 1:		Line 1:

	==Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)==		==Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)==
-	<StructureSection load='3qn7' size='340' side='right' caption='[[3qn7]], [[Resolution\|resolution]] 1.90Å' scene=''>	+	<StructureSection load='3qn7' size='340' side='right'caption='[[3qn7]], [[Resolution\|resolution]] 1.90Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[3qn7]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QN7 OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=3QN7 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[3qn7]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QN7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3QN7 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ZBR:1,3,5-TRIS(BROMOMETHYL)BENZENE'>ZBR</scene></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ZBR:1,3,5-TRIS(BROMOMETHYL)BENZENE'>ZBR</scene></td></tr>
-	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[1lmw\|1lmw]], [[2nwn\|2nwn]]</td></tr>	+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[1lmw\|1lmw]], [[2nwn\|2nwn]]</div></td></tr>
-	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">PLAU ([~~http~~://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>	+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">PLAU ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
-	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [~~http~~://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </span></td></tr>	+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[https://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [https://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=3qn7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qn7 OCA], [~~http~~://pdbe.org/3qn7 PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=3qn7 RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/3qn7 PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=3qn7 ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3qn7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qn7 OCA], [https://pdbe.org/3qn7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3qn7 RCSB], [https://www.ebi.ac.uk/pdbsum/3qn7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3qn7 ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
-	[[~~http~~://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[~~http~~://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>	+	[[https://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[https://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>
	== Function ==		== Function ==
-	[[~~http~~://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.	+	[[https://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 25:		Line 25:

	==See Also==		==See Also==
-	*[[Urokinase\|Urokinase]]	+	*[[Urokinase 3D Structures\|Urokinase 3D Structures]]
	== References ==		== References ==
	<references/>		<references/>
Line 31:		Line 31:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: U-plasminogen activator]]		[[Category: U-plasminogen activator]]
	[[Category: Angelini, A]]		[[Category: Angelini, A]]

OCA at 14:07, 11 August 2016

OCA — Thu, 11 Aug 2016 14:07:50 GMT

←Older revision		Revision as of 14:07, 11 August 2016
Line 1:		Line 1:
		+
	==Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)==		==Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)==
	<StructureSection load='3qn7' size='340' side='right' caption='[[3qn7]], [[Resolution\|resolution]] 1.90Å' scene=''>		<StructureSection load='3qn7' size='340' side='right' caption='[[3qn7]], [[Resolution\|resolution]] 1.90Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[3qn7]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/~~Homo_sapiens Homo sapiens~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QN7 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3QN7 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[3qn7]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QN7 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3QN7 FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ZBR:1,3,5-TRIS(BROMOMETHYL)BENZENE'>ZBR</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ZBR:1,3,5-TRIS(BROMOMETHYL)BENZENE'>ZBR</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[1lmw\|1lmw]], [[2nwn\|2nwn]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[1lmw\|1lmw]], [[2nwn\|2nwn]]</td></tr>
-	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">PLAU ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 ~~Homo sapiens~~])</td></tr>	+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">PLAU ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3qn7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qn7 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3qn7 RCSB], [http://www.ebi.ac.uk/pdbsum/3qn7 PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3qn7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qn7 OCA], [http://pdbe.org/3qn7 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3qn7 RCSB], [http://www.ebi.ac.uk/pdbsum/3qn7 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3qn7 ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 21:		Line 22:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 3qn7" style="background-color:#fffaf0;"></div>

	==See Also==		==See Also==
Line 28:		Line 30:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Homo sapiens~~]]	+	[[Category: Human]]
	[[Category: U-plasminogen activator]]		[[Category: U-plasminogen activator]]
	[[Category: Angelini, A]]		[[Category: Angelini, A]]

OCA at 11:55, 20 January 2015

OCA — Tue, 20 Jan 2015 11:55:06 GMT

←Older revision		Revision as of 11:55, 20 January 2015
Line 1:		Line 1:
-	~~{{STRUCTURE_3qn7\| PDB=3qn7 \| SCENE= }}~~	+	==Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)==
-	===Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)===	+	<StructureSection load='3qn7' size='340' side='right' caption='[[3qn7]], [[Resolution\|resolution]] 1.90Å' scene=''>
-	~~{{ABSTRACT_PUBMED_22304751}}~~	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[3qn7]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QN7 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3QN7 FirstGlance]. <br>
-	==Disease==	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ZBR:1,3,5-TRIS(BROMOMETHYL)BENZENE'>ZBR</scene></td></tr>
		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[1lmw\|1lmw]], [[2nwn\|2nwn]]</td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">PLAU ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 Homo sapiens])</td></tr>
		+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/U-plasminogen_activator U-plasminogen activator], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.21.73 3.4.21.73] </span></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3qn7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3qn7 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3qn7 RCSB], [http://www.ebi.ac.uk/pdbsum/3qn7 PDBsum]</span></td></tr>
		+	</table>
		+	== Disease ==
	[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[http://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>		[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[http://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>
-		+	== Function ==
-	==Function==	+
	[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.		[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	From a large combinatorial library of chemically constrained bicyclic peptides we isolated a selective and potent (K(i) = 53 nM) inhibitor of human urokinase-type plasminogen activator (uPA) and crystallized the complex. This revealed an extended structure of the peptide with both peptide loops engaging the target to form a large interaction surface of 701 A(2) with multiple hydrogen bonds and complementary charge interactions, explaining the high affinity and specificity of the inhibitor. The interface resembles that between two proteins and suggests that these constrained peptides have the potential to act as small protein mimics.

-	~~==About this Structure==~~	+	Bicyclic peptide inhibitor reveals large contact interface with a protease target.,Angelini A, Cendron L, Chen S, Touati J, Winter G, Zanotti G, Heinis C ACS Chem Biol. 2012 May 18;7(5):817-21. doi: 10.1021/cb200478t. Epub 2012 Feb 15. PMID:22304751<ref>PMID:22304751</ref>
-	~~[[3qn7]] is a 2 chain structure~~ with ~~sequence from [http~~:~~//en~~.~~wikipedia~~.~~org~~/~~wiki/Homo_sapiens Homo sapiens]~~. ~~Full crystallographic information is available from [http~~://~~oca~~.~~weizmann~~.ac.il/~~oca-bin/ocashort?id=3QN7 OCA].~~	+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>

	==See Also==		==See Also==
	*[[Urokinase\|Urokinase]]		*[[Urokinase\|Urokinase]]
-		+	== References ==
-	==~~Reference~~==	+	<references/>
-	~~<ref group="xtra">PMID:017692534</ref>~~<references ~~group="xtra"~~/><~~references~~/>	+	__TOC__
		+	</StructureSection>
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	[[Category: U-plasminogen activator]]		[[Category: U-plasminogen activator]]
-	[[Category: Angelini, A.]]	+	[[Category: Angelini, A]]
-	[[Category: Cendron, L.]]	+	[[Category: Cendron, L]]
-	[[Category: Heinis, C.]]	+	[[Category: Heinis, C]]
-	[[Category: Touati, J.]]	+	[[Category: Touati, J]]
-	[[Category: Winter, G.]]	+	[[Category: Winter, G]]
-	[[Category: Zanotti, G.]]	+	[[Category: Zanotti, G]]
	[[Category: Bicyclic peptide inhibitor]]		[[Category: Bicyclic peptide inhibitor]]
	[[Category: Chymotrypsin fold]]		[[Category: Chymotrypsin fold]]

OCA at 21:59, 10 April 2013

OCA — Wed, 10 Apr 2013 21:59:32 GMT

←Older revision		Revision as of 21:59, 10 April 2013
Line 1:		Line 1:
	{{STRUCTURE_3qn7\| PDB=3qn7 \| SCENE= }}		{{STRUCTURE_3qn7\| PDB=3qn7 \| SCENE= }}
	===Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)===		===Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)===
-	{{~~ABSTRACT_PUBMED_17692534~~}}	+	{{ABSTRACT_PUBMED_22304751}}

	==Disease==		==Disease==
-	[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[http://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>	+	[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[http://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>

	==Function==		==Function==
Line 16:		Line 16:

	==Reference==		==Reference==
-	<ref group="xtra">PMID:017692534~~</ref><ref group="xtra">PMID:008591045~~</ref><references group="xtra"/><references/>	+	<ref group="xtra">PMID:017692534</ref><references group="xtra"/><references/>
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	[[Category: U-plasminogen activator]]		[[Category: U-plasminogen activator]]

OCA at 22:39, 24 March 2013

OCA — Sun, 24 Mar 2013 22:39:50 GMT

←Older revision		Revision as of 22:39, 24 March 2013
Line 1:		Line 1:
-	[[Image:3qn7.jpg\|left\|200px]]
-
-	<!--
-	The line below this paragraph, containing "STRUCTURE_3qn7", creates the "Structure Box" on the page.
-	You may change the PDB parameter (which sets the PDB file loaded into the applet)
-	or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
-	or leave the SCENE parameter empty for the default display.
-	-->
	{{STRUCTURE_3qn7\| PDB=3qn7 \| SCENE= }}		{{STRUCTURE_3qn7\| PDB=3qn7 \| SCENE= }}
-
	===Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)===		===Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)===
		+	{{ABSTRACT_PUBMED_17692534}}

		+	==Disease==
		+	[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Defects in PLAU are the cause of Quebec platelet disorder (QPD) [MIM:[http://omim.org/entry/601709 601709]]. QPD is an autosomal dominant bleeding disorder due to a gain-of-function defect in fibrinolysis. Although affected individuals do not exhibit systemic fibrinolysis, they show delayed onset bleeding after challenge, such as surgery. The hallmark of the disorder is markedly increased PLAU levels within platelets, which causes intraplatelet plasmin generation and secondary degradation of alpha-granule proteins.<ref>PMID:20007542</ref>

-	~~<!--~~	+	==Function==
-	~~The line below this paragraph, {{ABSTRACT_PUBMED_17692534}}, adds the Publication Abstract to the page~~	+	[[http://www.uniprot.org/uniprot/UROK_HUMAN UROK_HUMAN]] Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.
-	~~(as it appears on PubMed at~~ http://www.~~pubmed~~.~~gov), where 17692534 is~~ the ~~PubMed ID number~~.	+
-	~~-->~~	+
-	~~{{ABSTRACT_PUBMED_17692534}}~~	+

	==About this Structure==		==About this Structure==
	[[3qn7]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QN7 OCA].		[[3qn7]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QN7 OCA].
		+
		+	==See Also==
		+	*[[Urokinase\|Urokinase]]

	==Reference==		==Reference==
-	<ref group="xtra">PMID:017692534</ref><ref group="xtra">PMID:008591045</ref><references group="xtra"/>	+	<ref group="xtra">PMID:017692534</ref><ref group="xtra">PMID:008591045</ref><references group="xtra"/><references/>
	[[Category: Homo sapiens]]		[[Category: Homo sapiens]]
	[[Category: U-plasminogen activator]]		[[Category: U-plasminogen activator]]

OCA at 06:49, 15 February 2012

OCA — Wed, 15 Feb 2012 06:49:08 GMT

←Older revision		Revision as of 06:49, 15 February 2012
Line 1:		Line 1:
-	~~'''Unreleased structure'''~~	+	[[Image:3qn7.jpg\|left\|200px]]

-	The ~~entry 3qn7~~ is ~~ON HOLD~~ ~~until Mar 14 2013~~	+	<!--
		+	The line below this paragraph, containing "STRUCTURE_3qn7", creates the "Structure Box" on the page.
		+	You may change the PDB parameter (which sets the PDB file loaded into the applet)
		+	or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
		+	or leave the SCENE parameter empty for the default display.
		+	-->
		+	{{STRUCTURE_3qn7\| PDB=3qn7 \| SCENE= }}

-	~~Authors: Angelini, A., Cendron, L., Touati, J., Winter, G., Zanotti, G., Heinis, C.~~	+	===Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)===

-	~~Description: Potent and selective bicyclic peptide inhibitor~~ (~~UK18~~) ~~of human urokinase~~-~~type~~ plasminogen activator~~(uPA)~~	+
		+	<!--
		+	The line below this paragraph, {{ABSTRACT_PUBMED_17692534}}, adds the Publication Abstract to the page
		+	(as it appears on PubMed at http://www.pubmed.gov), where 17692534 is the PubMed ID number.
		+	-->
		+	{{ABSTRACT_PUBMED_17692534}}
		+
		+	==About this Structure==
		+	[[3qn7]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3QN7 OCA].
		+
		+	==Reference==
		+	<ref group="xtra">PMID:017692534</ref><ref group="xtra">PMID:008591045</ref><references group="xtra"/>
		+	[[Category: Homo sapiens]]
		+	[[Category: U-plasminogen activator]]
		+	[[Category: Angelini, A.]]
		+	[[Category: Cendron, L.]]
		+	[[Category: Heinis, C.]]
		+	[[Category: Touati, J.]]
		+	[[Category: Winter, G.]]
		+	[[Category: Zanotti, G.]]
		+	[[Category: Bicyclic peptide inhibitor]]
		+	[[Category: Chymotrypsin fold]]
		+	[[Category: Extracellular]]
		+	[[Category: Hydrolase-hydrolase inhibitor complex]]
		+	[[Category: Serine protease]]

OCA at 05:54, 8 February 2012

OCA — Wed, 08 Feb 2012 05:54:47 GMT

←Older revision		Revision as of 05:54, 8 February 2012
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 3qn7 is ON HOLD until ~~Feb 08~~ 2013	+	The entry 3qn7 is ON HOLD until Mar 14 2013

	Authors: Angelini, A., Cendron, L., Touati, J., Winter, G., Zanotti, G., Heinis, C.		Authors: Angelini, A., Cendron, L., Touati, J., Winter, G., Zanotti, G., Heinis, C.

	Description: Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)		Description: Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)

OCA at 09:39, 23 February 2011

OCA — Wed, 23 Feb 2011 09:39:04 GMT

←Older revision		Revision as of 09:39, 23 February 2011
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 3qn7 is ON HOLD	+	The entry 3qn7 is ON HOLD until Feb 08 2013

	Authors: Angelini, A., Cendron, L., Touati, J., Winter, G., Zanotti, G., Heinis, C.		Authors: Angelini, A., Cendron, L., Touati, J., Winter, G., Zanotti, G., Heinis, C.

	Description: Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)		Description: Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activator(uPA)

OCA: Protected "3qn7" [edit=sysop:move=sysop]

OCA — Wed, 16 Feb 2011 05:22:45 GMT

Protected "3qn7" [edit=sysop:move=sysop]

←Older revision

Revision as of 05:22, 16 February 2011